tagamet tablets 800 mg
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains cimetidine 800,0 mg
tagamet tablets 400 mg
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains cimetidine 400 mg
tagamet iv 400 infusion (parenteral)
pharmacare limited û woodmead - infusion (parenteral) - see ingredients - each 100,0 ml solution contains cimetidine 400,0mg
tagamet tab 200 mg
مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - cimetidine 200 mg - 200 mg
tagamet tab 400 mg
مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - cimetidine 400 mg - 400 mg
tagamet injection 200mg (タガメット注射液200mg)
sumitomo pharma co.,ltd. - cimetidine - injection
tikosyn- dofetilide capsule
pfizer laboratories div pfizer inc - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide 0.125 mg - tikosyn is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because tikosyn can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). tikosyn is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. tikosyn has not been shown to be effective in patients with paroxysmal atrial fibrillation. tikosyn is contraindicated in patients with congenital or acquired long qt syndromes. tikosyn should not be used in patients with a baseline qt interval or qtc >440 msec (500 msec in patients wi
tikosyn- dofetilide capsule
avera mckennan hospital - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide 0.5 mg - tikosyn is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because tikosyn can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). tikosyn is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. tikosyn has not been shown to be effective in patients with paroxysmal atrial fibrillation. tikosyn is contraindicated in patients with congenital or acquired long qt syndromes. tikosyn should not be used in patients with a baseline qt interval or qtc >440 msec (500 msec in patients wi
dofetilide capsule
greenstone llc - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide 0.125 mg - dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide capsules are contraindicated in patients with congenital or acquired long qt syndromes. dofetilide capsules should not be used in patients wi
dofetilide capsule
mayne pharma inc. - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide 0.125 mg - dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide capsules can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide capsules are contraindicated in patients with congenital or acquired long qt syndromes. dofetilide capsules should not be used in pa